Pruritic papular eruption of HIV: Difference between revisions

(Text replacement - "==Differential==" to "==Differential Diagnosis==")
 
(8 intermediate revisions by 4 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Most common rash of HIV<ref>Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. Zancanaro PC et al. J Am Acad Dermatol. 2006 Apr;54(4):581-8.</ref>
{{Skin anatomy background images}}
*Most common [[rash]] of [[HIV]]<ref>Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. Zancanaro PC et al. J Am Acad Dermatol. 2006 Apr;54(4):581-8.</ref>
*Presenting symptom of HIV in up to ~80% cases
*Presenting symptom of HIV in up to ~80% cases
*3x more common when CD4 count < 200
*3x more common when CD4 count < 200
Line 7: Line 8:


==Clinical Features==
==Clinical Features==
*Pruritic
[[File:PMC4808702 gr1.png|thumb|Intensely pruritic papular rash with greatest severity on the extensor surfaces of extremities.]]
*Diffusely, symmetrically distributed rash
[[File:PMC3195174 IJSTD-32-118-g001.png|thumb|Pruritic papular eruptions as presenting illness of HIV.]]
*Discrete red bumps initially
[[File:PMC3168063 IJSTD-30-79-g002.png|thumb|Pruritic papular lesions on hands.]]
*Extremities/trunk > face
*[[Pruritus|Pruritic]]
*Mucous membrane sparing
*Diffusely, symmetrically distributed [[rash]]
**Discrete red bumps initially
**Extremities/trunk > face
**Mucous membrane sparing


==Differential Diagnosis==
==Differential Diagnosis==
*[[Folliculitis]]
*[[Folliculitis]]
*[[Cellulitis]]
*[[Cellulitis]]
*Fungal infection
*[[Fungal infection]]
*HSV infection
*[[HSV]] infection
*HPV warts
*[[HPV]] warts
*Drug reaction
*[[drug rash|Drug reaction]]
*Insect bites
*[[Insect bites]]
*[[Porphyria]]
*[[Porphyria]]


{{HIV associated conditions}}
{{HIV associated conditions}}


==Diagnosis==
==Evaluation==
*Appropriate clinical setting
*Appropriate clinical setting


==Management==
==Management==
*Initially topical steroids, emollients, PO antihistamines
*Initially [[topical steroids]], emollients, PO [[antihistamines]]
*[[Doxepin]] 25 mg QHS later line PO med for those without TCA contraindication<ref>Maurer. Dermatologic Manifestations of HIV Infection. Perspective – Dermatologic Manifestations Volume 13 Issue 5 December 2005/January 2006.</ref>
*UV phototherapy for refractory cases
*UV phototherapy for refractory cases


==Disposition==
==Disposition==
*Outpatient dermatology f/u
*Outpatient dermatology follow up
*Average time for recurrence of skin condition ~8 wks
*Average time for recurrence of skin condition ~8 wks



Latest revision as of 17:29, 11 December 2024

Background

Normal dermal anatomy.
  • Most common rash of HIV[1]
  • Presenting symptom of HIV in up to ~80% cases
  • 3x more common when CD4 count < 200
  • Up to 46% of HIV patients have this rash at some time of disease course
  • Diagnosis of exclusion

Clinical Features

Intensely pruritic papular rash with greatest severity on the extensor surfaces of extremities.
Pruritic papular eruptions as presenting illness of HIV.
Pruritic papular lesions on hands.
  • Pruritic
  • Diffusely, symmetrically distributed rash
    • Discrete red bumps initially
    • Extremities/trunk > face
    • Mucous membrane sparing

Differential Diagnosis

HIV associated conditions

Evaluation

  • Appropriate clinical setting

Management

Disposition

  • Outpatient dermatology follow up
  • Average time for recurrence of skin condition ~8 wks

References

  1. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. Zancanaro PC et al. J Am Acad Dermatol. 2006 Apr;54(4):581-8.
  2. Gutteridge, David L MD, MPH, Egan, Daniel J. MD. The HIV-Infected Adult Patient in The Emergency Department: The Changing Landscape of the Disease. Emergency Medicine Practice: An Evidence-Based Approach to Emergency Medicine. Vol 18, Num 2. Feb 2016.
  3. Maurer. Dermatologic Manifestations of HIV Infection. Perspective – Dermatologic Manifestations Volume 13 Issue 5 December 2005/January 2006.